Clinical Trials
54
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (52 trials with phase data)• Click on a phase to view related trials
Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 231
- Registration Number
- NCT07039916
- Locations
- 🇺🇸
Site Number - 1017, Phoenix, Arizona, United States
🇺🇸Site Number - 1029, Rancho Mirage, California, United States
🇺🇸Site Number - 1004, San Francisco, California, United States
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 162
- Registration Number
- NCT07032662
- Locations
- 🇺🇸
Site Number - 1612, Tucson, Arizona, United States
🇺🇸Site Number - 1618, Carlsbad, California, United States
🇺🇸Site Number - 1619, Orange, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 210
- Registration Number
- NCT07018323
- Locations
- 🇺🇸
Site Number - 1020, Columbus, Georgia, United States
🇺🇸Site Number - 1008, Hialeah, Florida, United States
🇺🇸Site Number - 1000, Miami, Florida, United States
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 180
- Registration Number
- NCT06979531
- Locations
- 🇺🇸
Site Number - 1004, Tamarac, Florida, United States
🇺🇸Site Number - 1000, Memphis, Tennessee, United States
🇺🇸Site Number - 1001, Allen, Texas, United States
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 56
- Registration Number
- NCT06980805
- Locations
- 🇺🇸
Site Number - 1010, Anniston, Alabama, United States
🇺🇸Site Number - 1020, Birmingham, Alabama, United States
🇺🇸Site Number - 1018, San Diego, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Graves Disease Pipeline Shows Promise with 10+ Therapies in Development as TED Treatments Gain Regulatory Momentum
DelveInsight's 2025 pipeline analysis reveals 8+ key companies are developing 10+ novel Graves Disease treatment therapies across various clinical development phases.
Graves' Disease and Graft-versus-Host Disease: Pipeline Therapeutics Update
Several companies are actively developing novel therapies for Graves' Disease, targeting mechanisms like IGF-1R and FcRn.